MedTrace Logo

A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

NCT06999031 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-05-31

No results posted yet for this study

Summary

This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-105-12 in the participants with BCMA-positive relapsed/refractory multiple myeloma who previously received adequate but uneffective standard treatments.

Conditions

Interventions

BIOLOGICAL

BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell

Chimeric Antigen Receptor Autologous T-cell

Sponsors & Collaborators

  • Cells & Genes Biotech (Shanghai) Co.,Ltd

    collaborator INDUSTRY

  • The First Affiliated Hospital of Nanchang University

    lead OTHER

Principal Investigators

  • Fei Li · The First Affiliated Hospital of Nanchang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-05
Primary Completion
2026-04-05
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06999031 on ClinicalTrials.gov